Drug Profile

Bempedoic acid/ezetimibe - Esperion Therapeutics

Alternative Names: ETC-1002/ezetimibe; Ezetimibe/bempedoic acid; Ezetimibe/ETC-1002; NEXLIZET; Nustendi

Latest Information Update: 27 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Esperion Therapeutics
Developer Daiichi Sankyo Europe; Esperion Therapeutics; Neopharm Ltd
Class Antihyperlipidaemics; Azetidines; Dicarboxylic acids; Fatty acids; Fluorobenzenes; Propanols; Small molecules
Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors; Cholesterol absorption inhibitors; Cholesterol synthesis inhibitors; NPC1L1 protein inhibitors; Peroxisome proliferator-activated receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

14 Aug 2025 Esperion therapeutics announces intention to launch Bempedoic/ezetimibe for Dyslipidaemia in Canada in the second quarter of 2026
11 Aug 2025 Esperion anticipates NDA approval for Cardiovascular disorders in Israel in the first half of 2026
08 May 2025 Bempedoic acid/ezetimibe licensed to HLS Therapeutics in Canada

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com